Vasoactive intestinal peptide and pituitary adenylate cyclase- activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation

Journal of Immunology

Volumn 162, Issue 8, 1999, Pages 4685-4696

  Delgado, Mario ^a,b   Munoz Elias, Ernesto J ^a   Gomariz, Rosa P ^b   Ganea, Doina ^a  

^a Department of Biological Sciences Rutgers University ^*  (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; NITRIC OXIDE SYNTHASE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME INDUCTION; HOST RESISTANCE; IMMUNOMODULATION; INFLAMMATORY CELL; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 0033561657     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Nathan, C. 1992. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:3501.
2. Nathan, C., and Q. W. Xie. 1994. Nitric oxide synthases: roles, tolls, and controls. Cell 78:915.
3. Lorsbach, R. B., W. J. Murphy, C. J. Lowenstein, S. H. Snyder, and S. W. Russell. 1993. Expression of the nitric oxide synthase gene in mouse macrophages activated for tumour cell killing. Molecular basis for the synergy between interferon-γ and lipopolysaccharide. J. Biol. Chem. 268:1908.
4. MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323.
5. Evans, C. H. 1995. Nitric oxide: what role does it play in inflammation and tissue destruction? Agents Actions 47:107.
6. Thiemermann, C., and J. Vane. 1990. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial LPSs in lhe rat in vivo. Eur. J. Pharmacol. 182:591.
7. McCartney-Francis, N., J. B. Allen, D. E. Mizel, J. E. Albina, Q. W. Xie, C. Nathan, and S. M. Wahl. 1993. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 178:749.
8. Said, S. I. 1996. Vasoactive intestinal peptide and nitric oxide: divergent roles in relation with tissue injury. Ann. NY Acad. Sci. 805:379.
9. Uchida, D., A. Arimura, A. Somogyvari-Vigh, S. Shioda, and W. A. Banks. 1996. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 736:280.
10. Said, S. I. 1985. Vasoactive intestinal peptide. In Airways Smooth Muscle: Peptide Receptors, Ion Channels and Signal Transduction. D. Raenburn and M. A. Giembycz, eds. Birkhauser Verlag Bassel, Switzerland, p. 87.
11. Ganea, D. 1996. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:61.
12. De la Fuente, M., M. Delgado, and R. P. Gomariz. 1996. VIP modulation of immune cell functions. Adv. Neuroimmunol. 6:75.
13. Martinez, C., M. Delgado, D. Pozo, J. Leceta, J. R. Calvo, D. Ganea, and R. P. Gomariz. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leukocyte Biol. 63:591.
14. Hernanz, A., E. Tato, M. De la Fuente, E. De Miguel, and F. Arnalich. 1996. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1β, interleukin-6, and tumor necrosis factor α production by whole blood cells from healthy young and old subjects. J. Neuroimmunol. 71:25.
15. Dewit, D., P. Gourlet, Z. Amraoui, P. Vertongen, F. Willems, P. Robberecht, and M. Goldman. 1998. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol. Lett. 60:57.
16. Delgado, M., D. Pozo, C. Martinez, J. Leceta, J. R. Calvo, D. Ganea, and R.P. Gomariz. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNFα production by macrophages: in vitro and in vivo studies. J. Immunol. 162:2358.
17. Delgado, M., C. Martinez, D. Pozo, J. R. Calvo, J. Leceta, D. Ganea, and R. P. Gomariz. 1999. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. 162:1200.
18. Said, S. I., H. I. Berisha, and H. Pakbaz. 1995. NMDA receptors outside the CNS: activation causes lung injury that is mediated by nitric oxide synthesis and prevented by VIP. Neuroscience 65:943.
19. Said, S. I., H. I. Berisha, and H. Pakbaz. 1996. Excitotoxicity in lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly (ADP-ribose) polymerase. Proc. Nat. Acad. Sci. USA 93:4688.
20. Green, L. C., D. A. Wagner, J. S. Glogowski, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum. 1982. Analysis of nitrate, nitrite and [15-N]nitrite in biological fluids. Ann. Biochem. 126:131.
21. Kim, H., H. S. Lee, K. T. Chang, T. H. Ko, K. J. Baek, and N. S. Kwon. 1995. Chloromethyl ketones block induction of nitric oxide synthase in murine macrophages by preventing activation of nuclear factor-κB J. Immunol. 154:4741.
22. Badger, A. M., M. N. Cook, M. W. Lark, T. M. Newman-Tarr, B. A. Swift, A. H. Nelson, F. C. Barone, and S. Kumar. 1998. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol. 161:467.
23. Brendt, D. S., and S. H. Snyder. 1990. Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. USA 87:682.
24. Melillo, G., L. S. Taylor, A. Brooks, G. W. Cox, and L. Varesio. 1996. Regulation of inducible nitric oxide synthase expression in IFN-γ-treated murine macrophages cultures under hypoxic conditions. J. Immunol. 157:2638.
25. Yang, J., I. Kawamura, H. Zhu, and M. Mitsuyama. 1995. Involvement of natural killer cells in nitric oxide production by spleen cells after stimulation with Mycobacterium bovis BCG. J. Immunol. 155:5728.
26. Delgado, M., C. Martinez, M. Johnson, R. P. Gomariz, and D. Ganea. 1996. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) in murine lymphocytes. J. Neuroimmunol. 68:27.
27. Schreiber, E., P. Metthias, M. M. Muller, and W. Shaffner. 1989. Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. Nucleic Acids Res. 17:6419.
28. Lowenstein, C. J., E. W. Alley, P. Raval, A. M. Snowman, S. H. Synder, S. W. Russel, and W. J. Murphy. 1993. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon-γ and lipopolysaccharide. Proc. Natl. Acad. Sci. USA 90:9730.
29. Xie, Q. W., R. Wishnan, and C. Nathan. 1993. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon γ and bacterial lipopolysaccharide. J. Exp. Med. 177:1779.
30. Harmar, A. J., A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, S. A. Wank, and J. A. Washeck. 1998. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol. Rev. 50:625.
31. Delgado, M., D. Pozo, C. Martinez, E. Garrido, J. Leceta, J. R. Calvo, and R. P. Gomariz. 1996. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul. Pept. 62:161.
32. Pozo, D., M. Delgado, C. Martinez, R. P. Gomariz, J. M. Guerrero, J. R. Calvo. 1997. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptor in rat peritoneal macrophages. Biochim. Biophys. Acta 1359:250.
33. Delgado, M., E. J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D. E. Brenneman, R. P. Gomariz, and D. Ganea. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit TNFα transcriptional activation by regulating NF-κB and CREB/c-Jun. J. Biol. Chem. 273:31436.
34. Gourlet, P., A. Vandermeers, P. Vertongen, J. Ratche, P. De Neef, J. Cnudde, M. Waelbroeck, and P. Robberecht. Development of high affinity selective VIP1 receptor agonists. Peptides 18:1539.
35. Xia, M., S. P. Sreedharan, D. R. Bolin, G. O. Gaufo, and E. J. Goetzl. 1997. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:629.
36. Moro, O., and E. A. Lerner. 1996. Maxadilan, the vasodilator peptide from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J. Biol. Chem. 271:966.
37. Gourlet, P., M. C. Vandermeers-Piret, J. Rathe, P. De Neef, and P. Robberecht. 1995. Fragments of the pituitary adenylate cyclase-activating polypeptide discriminate between type I and II recombinant receptors. Eur. J. Pharmacol. 287:7.
38. Gourlet, P., P. De Neef, J. Cnudde, M. Waelbroeck, and P. Robberecht. 1997. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18:1555.
39. Alleva, D. G., C. J. Burger, and K. D. Elgert. 1994. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production. J. Immunol. 153: 1674.
40. Chartrain, N. S., D. A. Geller, P. P. Koty, N. F. Sitrin, A. K. Nussler, E. P. Hoffman, T. R. Billiar, N. I. Hutchinson, and J. S. Mudgett. 1994. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J. Biol. Chem. 269:6765.
41. van Deuren, M., A. S. M. Dofferhoff, and J. W. M. van der Meer. 1992. Cytokines and the response to infection. J. Pathol. 168:349.
42. Heinzel, F. P., R. M. Rerko, P. Ling, J. Hakimi, and D. S. Schoenhaut. 1994. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect. Immun. 62:4244.
43. Wysocka, M., M. Kubin, L. Q. Vieira, L. Ozmen, G. Garotta, P. Scott, and G. Trinchieri. 1995. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25:672.
44. Trepicchio, W., M. Bozza, G. Pedneault, and A. Dorner. 1996. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J. Immunol. 157: 3627.
45. Muchamuel, T., S. Menon, P. Pisacane, M. C. Howard, and D. A. Cockayne. 1997. IL-13 protects mice from LPS-induced lethal endotoxemia. J. Immunol. 158:2898.
46. Marchant, A., C. Bruyns, P. Vandenabeele, M. Ducarme, C. Gerard, A. Delvaux, D. De Groote, D. Abramowicz, T. Velu, and M. Goldman. 1994. Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur. J. Immunol. 24:1167.
47. Howard, M., T. Muchamuel, S. Andrade, and S. Menon. 1993. Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205.
48. Gerard, C., C. Bruyns, A. Marchant, D. Abramowicz, P. Vandenabeele, A. Delvaux, W. Fiers, M. Goldman, and T. Velu. 1993. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:547.
49. Delgado, M., E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162:1707.
50. Said, S. I. 1996. Molecules that protect: the defense of neurons and other cells. J. Clin. Invest. 97:2163.
51. Bandyopadhyay, A., S. Chakder, and S. Rattan. 1997. Regulation of inducible and neuronal nitric oxide synthase gene expression by interferon-γ and VIP. Am. J. Physiol. 272:C1790.
52. Xin, Z., H. Tang, and D. Ganea. 1994. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via TCR/ CD3 complex. J. Neuroimmunol. 54:59.
53. Martinez, C., M. Delgado, R. P. Gomariz, D. Ganea. 1996. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J. Immunol. 156:4128.
54. Gourlet, P., J.-P., Vilardaga, P. De Neef, M. Waelbroeck, A. Vandermeers, and P. Robberecht. 1996. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides 17:825-829.
55. O'Donnell, M., R. J. Garippa, N. C. O'Neill, D. R. Bolin, and J. M. Cottrell. 1991. Structure-activity studies of vasoactive intestinal polypeptide. J. Biol. Chem. 266:6389.
56. Rawlings, S. R., and M. Hezareh. 1996. Pituitary adenylate cyclase activating polypeptide and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr. Rev. 17:4.
57. Nathan, C., and Q. W. Xie. 1994. Regulation of the biosynthesis of nitric oxide. J. Biol. Chem. 269:13725.
58. Kamijo, R., H. Harada, T. Matsuyama, M. Bosland, J. Gerecitano, D. Shapiro, J. Le, S. I. Koh, T. Kimura, S. J. Green, T. W. Mak, T. Taniguchi, and J. Vilcek. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 264:1612.
59. Martin, E., C. Nathan, and Q. W. Xie. 1994. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J. Exp. Med. 180:977.
60. Wang, P., P. Wu, M. I. Siegel, R. W. Egan, and M. M. Billah. 1995. Interleukin (IL)-10 inhibits nuclear factor κB (NFκB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem. 270:9558.
61. Arsura, M., M. Wu, and G. E. Sonenshein. 1996. TGFβ1 inhibits NF-κB/Rel activity inducing apoptosis of B cells: transcriptional activation of IκBa. Immunity 5:31.
62. Auphan, N., J. A. Di Donato, C. Rosette, A. Helmberg, and M. Karin. 1995. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286.
63. Suzuki, Y. J., M. Mizuno, and L. Packer. 1994. Signal transduction for nuclear factor-κB activation. Proposed location of antioxidant-inhibitable step. J. Immunol. 153:5008.
64. Harada, H., K. Willison, J. Sakarkibara, M. Miyamoto, T. Fujita, and T. Taniguchi. 1990. Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell 63:303.
65. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415.
66. Ivashkiv, L. B., E. M. Schmitt, and A. Castro. 1996. Inhibition of transcription factor Stat1 activity in mononuclear cell cultures and T cells by the cyclic AMP signaling pathway. J. Immunol. 157:1415.
67. Sengupta, T. K., E. M. Schmitt, and L. B. Ivashkiv. 1996. Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Proc. Natl. Acad. Sci. USA 93:9499.
68. Kawada, N., M. Uoya, S. Seki, T. Kuroki, and K. Kobayashi. 1997. Regulation by cAMP of STAT1 activation in hepatic stellate cells. Biochem. Biophys. Res. Commun. 233:464.
69. Harbrecht, B. G., T. R. Billiar, J. Stadler, A. J. Demetris, J. Ochoa, R. D. Curran, and R. L. Simmons. 1992. Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury. J. Leukocyte Biol. 52:390.
70. Cobb, J. P., C. Natanson, W. D. Hoffman, R. F. Lodato, S. Banks, C. A. Koev, M. A. Solomon, E. J. Elin, J. M. Hosseini, and L. R. Danner. 1992. Nω-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J. Exp. Med. 176:1175.
71. Delgado, M., E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages: subsequent effect on IFN-γ synthesis by T cells. J. Neuroimmunol. In press.